{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:54:16Z","timestamp":1785416056007,"version":"3.56.0"},"reference-count":47,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Research and Human Retroviruses"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>We assessed the effectiveness and safety of switching to generic dolutegravir\/lamivudine (DTG\/3TC) among People living with Human Immunodeficiency Virus (PWH) in Western India. In this single-center, retrospective observational study, PWH, who switched to DTG\/3TC, were followed for virologic, immunologic, and clinical effectiveness, and safety, including weight changes, hyperglycemia, and dyslipidemia. Multivariate linear mixed-effects models were used to predict average change in weight adjusted for age, sex, duration of previous antiretroviral (ARV) regimens, and baseline weight. From May 2017 to July 2022, out of 434 PWH switched to DTG\/3TC, 304 with at least 1 follow-up visit were included. Median [interquartile range (IQR)] age was 54 (IQR 49\u201361) years and 70.1% were male. Prevalence of baseline comorbidities was 57.9% (hypertension\u201441.5%, chronic kidney disease\u201440.9%, and diabetes mellitus\u201418.8%). Reasons for switch were affordability (47.4%), desire for simplification (41.8%), ARV toxicities (19.1%), and concern about potential toxicities (10.2%). Median (IQR) duration of follow-up on DTG\/3TC was 40 (IQR 31\u201349) weeks. No virologic failure was observed. Rates of virologic suppression [viral load (VL) \u226420 copies\/mL or target not detected (TND)] at 12, 24, 48, 72, 96 and 120 weeks were 95.2%, 95.9%, 90%, 100%, 81.3%, and 88.4%, respectively. Only 9 (3%) PWH permanently discontinued DTG\/3TC. Predicted adjusted mean weight gain of +3.3\u2009kg was observed at 96 weeks. Switching from tenofovir disoproxil fumarate (TDF)\/emtricitabine or lamivudine (XTC)\/non-nucleoside reverse transcriptase inhibitor (NNRTI) and duration on DTG\/3TC were significantly associated with weight gain. Apart from trend in worsening hyperglycemia (nine PWH with new onset diabetes), no clinically significant change in lipids and estimated glomerular filtration rate (eGFR) was documented. Switching to DTG\/3TC is an effective and safe option among virologically suppressed PWH with high comorbidity burden in India. In view of the several advantages of DTG\/3TC, it may be considered for potential scale-up in the right population, both in private and public health care settings in India.<\/jats:p>","DOI":"10.1089\/aid.2022.0167","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T04:39:19Z","timestamp":1702010359000},"page":"204-215","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness, Weight Changes, and Metabolic Outcomes on Switch to Generic Dolutegravir\/Lamivudine Among People with HIV in Western India: An Observational Study"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4571-650X","authenticated-orcid":false,"given":"Sanjay","family":"Pujari","sequence":"first","affiliation":[{"name":"Institute of Infectious Diseases, Pune, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Gaikwad","sequence":"additional","affiliation":[{"name":"Institute of Infectious Diseases, Pune, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhrud","family":"Panchawagh","sequence":"additional","affiliation":[{"name":"Biostatistics Consultant, Pune, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Chitalikar","sequence":"additional","affiliation":[{"name":"Institute of Infectious Diseases, Pune, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kedar","family":"Joshi","sequence":"additional","affiliation":[{"name":"Institute of Infectious Diseases, Pune, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitrangi","family":"Rohekar","sequence":"additional","affiliation":[{"name":"Institute of Infectious Diseases, Pune, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diagamber","family":"Dabhade","sequence":"additional","affiliation":[{"name":"Institute of Infectious Diseases, Pune, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Bele","sequence":"additional","affiliation":[{"name":"Institute of Infectious Diseases, Pune, India."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,4,11]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.5582\/ddt.2021.01068"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10020433"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003070"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac036"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac130"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00100-4"},{"key":"e_1_3_6_8_2","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv [Last accessed: October11 2022]."},{"key":"e_1_3_6_9_2","unstructured":"European AIDS Clinical Society. EACS Guidelines Version 11.0. October 2021. https:\/\/www.eacsociety.org\/media\/final2021eacsguidelinesv11.0_oct2021.pdf [Last accessed: October 11 2022]."},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003047"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003053"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13373"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211034176"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570162X20666220514165728"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/v14030524"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211038504"},{"key":"e_1_3_6_17_2","unstructured":"National AIDS Control Organization. Sankalk: Status of National AIDS Response 4th edition. 2022. Available from: https:\/\/naco.gov.in\/sites\/default\/files\/Sankalak_Report_1.pdf [Last accessed: April14 2022]."},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002903"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-020-0349-x"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_225_20"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-11-201306040-00007"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2022.07.009"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.27.7.891"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25085"},{"key":"e_1_3_6_26_2","unstructured":"Tenofovir Alafenamide. Prescribing Information. Gliead Sciences. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208464s008lbl.pdf [Last accessed: October18 2022]."},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.4102\/sajhivmed.v19i1.817"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir269"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002655"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2021.0041"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002787"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2022.2128766"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2022.07.022"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab429"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz256"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25961"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01457-y"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003101"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001525"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003083"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1073"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1219"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1403"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac355"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003278"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3378"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/cld.1125"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13217"}],"container-title":["AIDS Research and Human Retroviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/aid.2022.0167","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2022.0167","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2022.0167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:17:05Z","timestamp":1777367825000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/aid.2022.0167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1089\/aid.2022.0167"],"URL":"https:\/\/doi.org\/10.1089\/aid.2022.0167","relation":{},"ISSN":["0889-2229","1931-8405"],"issn-type":[{"value":"0889-2229","type":"print"},{"value":"1931-8405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}